Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASN004 in advanced solid tumors
NCT04410224Phase 1Completed
- Sponsor
- Kirilys Therapeutics
- Start
- Apr 2022
- Primary completion
- May 2024
- Modality
- Small Molecules, Cyclic Peptides, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ASN004 in solid tumor, sponsored by Kirilys Therapeutics. Primary endpoint: Maximum Tolerated Dose of ASN004 at 28 days. Started Apr 2022; status: completed.
02
Drugs
ASN004
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04410224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04410224.